Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients

Transplantation

Volumn 69, Issue 3, 2000, Pages 389-394

  Fishman, Jay A ^a   Doran, Maureen T ^a   Volpicelli, Sheila A ^a   Cosimi, A Benedict ^a   Flood, James G ^a   Rubin, Robert H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; GANCICLOVIR; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG EFFICACY; GRAFT INFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VIRUS RESISTANCE;

EID: 0034003610     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200002150-00014     Document Type: Article

References (46)

1. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 261: 3607.
2. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741.
3. Falagas ME, Snydman DR, Griffith J, Werner BG, Freeman R, Rohrer R. Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 1997; 25: 314.
4. Hibberd PL, Snydman DR. Cytomegalovirus infection in organ transplant recipients. Infect Dis Clin North Am 1995; 9: 863.
5. George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Am J Med 1997; 103: 106.
6. Reinke P, Fietze E, Ode-Hakim S, et al. Late acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994; 1: 1737.
7. Paya CV Wiesner RH, Hermans PE, et al. Risk factor for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993; 18: 185.
8. Richardson WP, Colvin RB, Cheeseman SH, et al. Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med 1981; 305: 57.
9. Suwansirikul S, Rao N, Dowling JN, Ho M. Primary and secondary cytomegalovirus infection. Arch Intern Med 1998; 37, 1026.
10. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody sero-positive renal transplant recipient treated with OKT3. Transplantation 1992; 53: 68.
11. Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev nfect Dis 1990; 12 (suppl 7): S754.
12. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997; 10: 86.
13. George MJ, Snydman DR, Werner BG, et al. Use of ganciclovir plus cytomegalovirus immune globulin to treat CMV pneumonia in orthotopic liver transplant recipients. The Boston Center for Liver Transplantation. Transplant Proc 1993; 25: 22.
14. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995; 123: 18.
15. Guerin C, Pozzetto B, Broyet C, Gaudin O, Berthoux F. Ganciclovir therapy of symptomatic cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1989; 4: 906.
16. Snydman DR, Falagas ME. Prevention of cytomegalovirus disease in transplant recipients. Lancet 1996: 1: 268.
17. Erice A, Jordan MC, Chace BA, Fletcher C, Chinnock BJ, Balfour HH Jr. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 1987; 257: 3082.
18. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995; 1: 69.
19. Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326: 1182.
20. Patel R, Snydman DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1279.
21. Hirsch MS, Schooley RT, Cosimi AB, et al. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. N Engl J Med 1983; 308: 1489.
22. Lake KD, Fletcher CV, Love KR, Brown DC, Joyce LD, Pritzker MR. Ganciclovir pharmacokinetics during renal impairment. Antimicrob Agent Chemother 1988; 32: 1899.
23. Sommadossi J-P, Bevan R, Ling T, et al. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis 1988; 10: 507.
24. Salamoun J, Sprta V, Sladek T, Smrz M. Determination of acyclovir in plasma by column liquid chromatography with fluorescence detection. J Chromatog 1987; 420, 197, 1987.
25. Field AK, Davies ME, DeWitt C, et al. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]-methyl)guanine: a selective inhibitor of herpes group virus replication. Proc Nat Acad Sci USA 1983; 80: 4139.
26. Smee DF, Martin JC, Verheyden JP, Matthews TR. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agent Chemother 1983; 23: 676.
27. Smith KO, Galloway KS, Kennell WL, Ogilvie KK, Radatus BK. A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl-)ethoxy]methyl]guanine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrob Agent Chemother 1982; 22: 55.
28. Russler SK, Tapper MA, Carrigan DR. Susceptibility of human herpesvirus 6 to acyclovir and ganciclovir. Lancet 1989; 2: 382.
29. Agut H, Collandre H, Aubin JT, et al. In vitro sensitivity of human herpesvirus-6 to antiviral drugs. Res Virol 1989; 140: 219.
30. Lin JC, Pagano JS. Cellular transformation by the herpesviruses and antiviral drugs. Pharmacol Ther 1985; 28: 135.
31. Freitas VR, Fraser-Smith EB, Matthews TR. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Antiviral Res 1989; 12: 205.
32. Fox JC, Griffiths PD, Emery VC. Quantification of human cytomegalovirus DNA using the polymerase chain reaction. J Gen Virol 1992; 73: 2405.
33. Sommadossi J-P, Carlisle, R. Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agent Chemother 1987; 31: 452.
34. Arevalo JF, Gonzalez C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995; 172: 951.
35. Campanero MA, Sadaba B, Garcia-Quetglas E, Azanza JR. Development and validation of a sensitive method for the determination of ganciclovir in human plasma samples by reversed-phase high-performance liquid chromatography. J Chromatog 1998; B, Biomed Sci Appl 706: 311.
36. Campanero MA, Sadaba B, Garcia-Quetglas E, Azanza JR. Development and validation of a sensitive method for the determination of ganciclovir in human plasma samples by reversed-phase high-performance liquid chromatography. J Chromatog 1998; B, Biomed Sci Appl 706: 311.
37. Pouteil-Noble C, Ecochard R, Landrivon G, et al. Cytomegalovirus infection - an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 1993; 55: 851.
38. O'Grady, J G., Alexander, G. J M., Sutherland, S., et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile duct syndrome after liver transplantation. Lancet 1998; 2: 302.
39. Reddehase MJ, Balthesen M, Rapp M, Jonic S, Pavic I, Koszinowski UH. The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med 1994; 179: 185.
40. Oroszlan S, Copeland TD, Smythers G, Summers MR, Gilden RV. Comparative primary structure analysis of the p30 protein of woolly monkey and gibbon type C viruses. Virology 1997; 413.
41. Chou S, Guentzel S, Michels KR, Miner RC, Drew WL. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995; 172: 239.
42. Boivin G, Erice A, Crane DD, Dunn DL, Balfour HH Jr. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J Infect Dis 1993; 168: 332.
43. Gilbert C, Handfield J, Toma E, Lalonde R, Bergeron MG, Boivin G. Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients. AIDS 1998; 12: 125.
44. Baldanti F, Underwood MR, Talarico CL, et al. The Cys607->Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrob Agent Chemother 1998; 42: 444.
45. Hanson MN, Preheim LC, Chou S, Talarico CL, Biron KK, Erice A. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob Agent Chemother 1995; 39: 1204.
46. Plotkin SA, Drew WL, Felsenstein D, Hirsch MS. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Infect Dis 1985; 152: 833.